Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
We will recruit men and non-pregnant women of any ethnic background between the age ≥ 18 and
≤ 90 years that have acute ischemic stroke and underwent Mechanical Thrombectomy (MT) with
TICI 2b or 2b following MT. These subject's will be will be randomized to placebo vs.
Tirofiban after consent is obtained. This will be administered via continuous IV starting
within 60 minutes of MT procedure completion. At the end of the 24 hour continuous IV dosing
period a CT angiography and CT perfusion (CTA/CTP) will be obtained. The rest of the subjects
inpatient hospital stay will be done per standard of care. The subject's NIHSS and modified
Rankin Score (mRS) will be assessed at 90 days.